First Manhattan Portfolio holdings
AUM
$35.4B
1-Year Return
24.51%
This Quarter Return
+1.83%
1 Year Return
+24.51%
3 Year Return
+86.41%
5 Year Return
+172.47%
10 Year Return
+337.52%
AUM
$34.1B
AUM Growth
+$366M
(+1.1%)
Cap. Flow
+$94.5M
Cap. Flow
% of AUM
0.28%
Top 10 Holdings %
Top 10 Hldgs %
59.17%
Holding
723
New
41
Increased
189
Reduced
269
Closed
43
Top Buys
| 1 |
ASML
ASML
|
$115M |
| 2 |
Berkshire Hathaway Class A
BRK.A
|
$76.3M |
| 3 |
Union Pacific
UNP
|
$56.1M |
| 4 |
NVIDIA
NVDA
|
$46.5M |
| 5 |
Applied Materials
AMAT
|
$41.2M |
Top Sells
| 1 |
Markel Group
MKL
|
$73.5M |
| 2 |
AZPN
Aspen Technology Inc
AZPN
|
$55.6M |
| 3 |
KKR & Co
KKR
|
$44.6M |
| 4 |
Apple
AAPL
|
$35.8M |
| 5 |
Mirion Technologies
MIR
|
$27.7M |
Sector Composition
| 1 | Financials | 44.82% |
| 2 | Technology | 21.62% |
| 3 | Consumer Discretionary | 7.18% |
| 4 | Communication Services | 6.65% |
| 5 | Healthcare | 6.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
TGB
651
Taseko Mines
TGB
$1.05B
| $194K | ﹤0.01% |
100,000
| – | – |
|
652
NOV
NOV
$4.95B
| $190K | ﹤0.01% |
12,995
-786
| -6% | -$11.5K |
|
653
Kennedy-Wilson Holdings
KW
$1.21B
| $187K | ﹤0.01% |
18,500
| – | – |
|
654
USCB Financial Holdings
USCB
$350M
| $178K | ﹤0.01% |
10,000
| – | – |
|
655
Aldeyra Therapeutics
ALDX
$334M
| $173K | ﹤0.01% |
34,745
| – | – |
|
656
Sabra Healthcare REIT
SBRA
$4.56B
| $173K | ﹤0.01% |
10,000
| – | – |
|
657
United-Guardian
UG
$39.1M
| $163K | ﹤0.01% |
17,062
| – | – |
|
658
Mativ Holdings
MATV
$680M
| $158K | ﹤0.01% |
14,506
-500
| -3% | -$5.45K |
|
659
Teekay
TK
$718M
| $157K | ﹤0.01% |
+22,686
| New | +$157K |
|
660
Roivant Sciences
ROIV
$8.82B
| $143K | ﹤0.01% |
12,100
+200
| +2% | +$2.37K |
|
661
Western New England Bancorp
WNEB
$255M
| $143K | ﹤0.01% |
15,518
| – | – |
|
662
Emerald Holding
EEX
$1.02B
| $122K | ﹤0.01% |
25,338
+3,575
| +16% | +$17.2K |
|
663
Valens Semiconductor
VLN
$205M
| $113K | ﹤0.01% |
43,458
| – | – |
|
664
Kaltura
KLTR
$226M
| $110K | ﹤0.01% |
50,000
| – | – |
|
665
Cerus
CERS
$255M
| $87.8K | ﹤0.01% |
57,000
| – | – |
|
666
Opko Health
OPK
$1.07B
| $76.1K | ﹤0.01% |
51,750
| – | – |
|
667
Immuneering
IMRX
$229M
| $71.1K | ﹤0.01% |
+32,325
| New | +$71.1K |
|
668
Vaalco Energy
EGY
$399M
| $49.5K | ﹤0.01% |
+11,337
| New | +$49.5K |
|
669
Taysha Gene Therapies
TSHA
$917M
| $49.3K | ﹤0.01% |
+28,500
| New | +$49.3K |
|
670
Arbutus Biopharma
ABUS
$805M
| $45.8K | ﹤0.01% |
14,000
| – | – |
|
|
MOGO
671
Mogo
MOGO
$43.5M
| $34.3K | ﹤0.01% |
26,400
| – | – |
|
672
Ovid Therapeutics
OVID
$87.5M
| $24.3K | ﹤0.01% |
26,000
| – | – |
|
673
Grove Collaborative
GROV
$62.7M
| $16.2K | ﹤0.01% |
11,662
| – | – |
|
|
OTLY
674
Oatly Group
OTLY
$524M
| $13.3K | ﹤0.01% |
1,000
| – | – |
|
675
Lucid Diagnostics
LUCD
$140M
| $10.3K | ﹤0.01% |
12,600
| – | – |
|